I want to agree. However, think about this from Neuromod's perspective: they have no way of knowing for sure whether audiologists and patients will pick this device up in the long run. There are at least two reasons for concern on their part:
- Sure, they (say to) have some positive results in a trial. However, their device does not seem to be the wonder cure. Any treatment trial I ever read reports a decreased impact of tinnitus over time (as opposed to silencing the tinnitus) (**). Also, if I understand correctly from the Q&A, the trial did not have a sham treatment condition.
- The second point is that they must be feeling the hot breath of other treatments — for example, the Shore device. Being the first to market is a vast but temporary advantage.
This gives them one sure shot at turning investment into profit: exploit the first-to-market advantage to sell as many devices as possible in the shortest time window possible. Once the hype wears off, who knows what will happen to the sales? But sure money now is better than possible money later.
I am sorry to be so cynical. However, without being cynical, I can't understand why it is so difficult for Neuromod to communicate openly with us. E-mails are answered with corporate speak. Their Twitter account replies to anything with the same precompiled lines of text. Signing up for the newsletter will not get you any news. Finally, their websites newsfeed only lists new hires. But likely, we have a few curated 'patient' (read: trial participant) stories on their website to keep us keen.
Again, I apologize for my negativity, but I hope we can have an open and critical debate about things. In fact, I would feel better if someone were to counter my arguments and prove me wrong.
Footnote: (**) Now we're on the topic, I want to say that I am also a little bit skeptical about the story of Clare on this forum.
I do not doubt her story, and I am grateful she's sharing it. However, seeing that her tinnitus disappeared six months after stopping the treatment makes me worried that the treatment was not the cause of her remission. Also, we don't even know which treatment group she was in (the study was double-blind). From the Q&A, I gather there is 66% chance she was in one of the groups that were designed to be contrasted with the standard treatment protocol. Therefore, there is 66% chance she was in a group that was not supposed to work.